SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
This review summarizes how SGLT2 inhibitors and GLP-1 receptor agonists protect the kidneys in diabetes through complementary mechanisms, noting SGLT2 inhibitors are stronger for preserving kidney function and GLP-1 agonists for lowering protein in the urine and heart-vessel events.
Background
Diabetic kidney disease is a leading cause of kidney failure and substantially raises cardiovascular risk. Despite renin-angiotensin system blockade, substantial residual risk remains, prompting integration of newer agents. This review synthesizes the evolving evidence for SGLT2 inhibitors and GLP-1 receptor agonists.
Key findings
Landmark trials including CREDENCE, DAPA-CKD, EMPA-KIDNEY, and FLOW demonstrate kidney-function preservation and reduced adverse outcomes. SGLT2 inhibitors appear more effective at mitigating glomerular hyperfiltration and lowering heart failure risk, whereas GLP-1 receptor agonists more strongly reduce albuminuria and atherosclerotic cardiovascular events. Direct head-to-head trials are lacking.
Clinical implications
The two classes act through complementary pathways, supporting combination therapy and precision-medicine approaches; the authors call for dedicated trials to define optimal sequencing and combined strategies in diabetic kidney disease.
Category
News
Source
Diabetes & Metabolism Journal
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.